Redefining pancreatic cancer management with tumor-agnostic precision medicine
NK Reddy, V Subbiah - Carcinogenesis, 2024 - academic.oup.com
Precision oncology and tumor-agnostic drug development provide hope for enhancing
outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged …
outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged …
A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?
VHF de Jesus, MDS Donadio… - Therapeutic …, 2024 - journals.sagepub.com
Pancreatic cancer is one of the deadliest malignancies in humans and it is expected to play
a bigger part in cancer burden in the years to come. Pancreatic ductal adenocarcinoma …
a bigger part in cancer burden in the years to come. Pancreatic ductal adenocarcinoma …
Lynch syndrome and somatic mismatch repair variants in pancreas cancer
Importance Microsatellite (MS) instability (MSI-H) occurs frequently in Lynch syndrome (LS)–
associated tumors and is associated with response to immune checkpoint blockade (ICB) …
associated tumors and is associated with response to immune checkpoint blockade (ICB) …
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF …
D Witte, I Pretzell, TM Reissig, A Stein… - Journal of cancer …, 2024 - Springer
Background Preclinical models of pancreatic cancer (PDAC) suggest a synergistic role for
combined MEK and autophagy signaling inhibition, as well as MEK and CDK4/6 pathway …
combined MEK and autophagy signaling inhibition, as well as MEK and CDK4/6 pathway …
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
The 5-year relative survival rate for pancreatic cancer is currently the lowest among all
cancer types with a dismal 13%. A Kirsten rat sarcoma virus (KRAS) gene mutation is …
cancer types with a dismal 13%. A Kirsten rat sarcoma virus (KRAS) gene mutation is …
[HTML][HTML] The road to overcome pancreatic cancer: Where are we?
A Tirpe, C Streianu, E Isachesku, I Simon… - Heliyon, 2024 - cell.com
Pancreatic cancer (PC) is an intricate malignancy with poor prognosis. In the present state of
the art review paper and clinical trial trend analysis, we explore the current clinically …
the art review paper and clinical trial trend analysis, we explore the current clinically …
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials
Despite improvements in overall cancer mortality, deaths related to pancreatic cancer
continue to rise. Following first-line treatment, second-line options are significantly limited …
continue to rise. Following first-line treatment, second-line options are significantly limited …
Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series
Background: KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a
distinct entity with unique biology. The therapeutic impact of matched targeted therapy in …
distinct entity with unique biology. The therapeutic impact of matched targeted therapy in …
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
T Doi, T Ishikawa, M Moriguchi… - Japanese Journal of …, 2025 - academic.oup.com
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis; however, advancements
in cancer genome profiling using next-generation sequencing have provided new …
in cancer genome profiling using next-generation sequencing have provided new …
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) targeting programmed cell
death protein-1 (PD-1/PD-L1) pathway as well as cytotoxic T-lymphocyte-associated protein …
death protein-1 (PD-1/PD-L1) pathway as well as cytotoxic T-lymphocyte-associated protein …